Lerner Lorena Raquel 4

4 · Keros Therapeutics, Inc. · Filed Feb 20, 2026

AI-generated summary of this filing

Updated Feb 20, 2026

Keros Therapeutics (KROS) CSO Lorena Lerner Sells 3,873 Shares

What Happened

Lorena Raquel Lerner, Chief Science Officer of Keros Therapeutics (KROS), sold 3,873 shares on 2026-02-18. The reported weighted-average sale price was $16.35 per share for total proceeds of approximately $63,324. This was a sale (not a purchase) and appears to have been executed to cover tax withholding related to vested restricted stock units.

Key Details

Transaction date: 2026-02-18; Form 4 filed: 2026-02-20 (appears timely within the two-business-day window).
Sale type/code: Open market or private sale (S).
Shares sold: 3,873; weighted-average price reported: $16.35; total proceeds: ~$63,324.
Price range: shares were sold in multiple transactions at prices ranging from $16.05 to $16.65 (filing includes a footnote offering to provide per-price breakdown on request).
Footnote: Issuer’s "sell-to-cover" policy — these sales were automatic to satisfy tax withholding on RSU vesting and were not at the reporting person’s discretion.
Shares owned after transaction: Not specified in the Form 4 filing.

Context

This transaction is a routine sell-to-cover tied to RSU vesting (tax withholding), which is common and not necessarily an indicator of the insider’s view on the company’s prospects. No 10b5-1 plan or unusual trading pattern is mentioned in the filing.

Form 4

Period: 2026-02-18

Chief Scientific Officer

Transactions

Footnotes (2)

[F1]The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.05 to $16.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Signature

/s/ Esther Cho, Attorney-in-Fact|2026-02-20

1 file